Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan acquired 90,300 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were acquired at an average cost of C$5.13 per share, for a total transaction of C$463,672.44.
Sime Armoyan also recently made the following trade(s):
- On Monday, September 16th, Sime Armoyan sold 300,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.13, for a total transaction of C$1,839,000.00.
Knight Therapeutics Stock Performance
Shares of GUD opened at C$5.19 on Friday. The company has a market capitalization of C$525.28 million, a PE ratio of -25.95, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. Knight Therapeutics Inc. has a one year low of C$5.07 and a one year high of C$6.23. The company's fifty day moving average price is C$5.71 and its 200 day moving average price is C$5.73.
Analysts Set New Price Targets
GUD has been the subject of several analyst reports. Stifel Nicolaus raised shares of Knight Therapeutics from a "hold" rating to a "buy" rating and lifted their price objective for the company from C$5.75 to C$6.75 in a research note on Tuesday, August 13th. Raymond James upgraded Knight Therapeutics to a "moderate buy" rating in a research note on Friday. Finally, Stifel Canada raised Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday, August 12th.
War on Elon Escalates…
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
Get Our Latest Stock Report on Knight Therapeutics
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
